| 2017 | 2018 | 2019 | 2020 (projected) | Revenues USD | 280 K | 11.38 M | 13.09 M | 14.12 M | Revenues | 378 K | 16.16 M | 18.58 M | 20.05 M |
Ownership Breakdown
| Retail Investors89.42% | Institutions10.1% |
| Retail Investors | 89.42 | |
| Insiders | 0.48 | |
| Institutions | 10.1 |
Is Benitec Biopharma (NASDAQ:BNTC) finally getting endorsement from investors?
 | By Rifka Kats | Macroaxis Story |
Benitec Biopharma Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to increase significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at 4.71 Million. The current year Earnings before Tax is expected to grow to about 5.1 M, whereas Average Assets are forecasted to decline to about 21.7 M. In this post, we will go over Benitec Biopharma. Why are we still confident in hope for a quick recovery. Here I will also go over some basic indicators that the company investors should consider in October.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Gabriel Shpitalnik
The company is undervalued at 8.45 per share with modest projections ahead. The firm shows a Beta (market volatility) of -0.1456, which signifies not very significant fluctuations relative to the market. Let's try to break down what Benitec's beta means in this case. As returns on the market increase, returns on owning Benitec Biopharma are expected to decrease at a much lower rate. During the bear market, Benitec Biopharma is likely to outperform the market. Even though it is essential to pay attention to Benitec Biopharma historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Benitec Biopharma Limited exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Benitec Biopharma has an expected return of -0.0353%. Please be advised to confirm Benitec Biopharma sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change to decide if Benitec Biopharma stock performance from the past will be repeated at some point in the near future. The performance of Benitec Biopharma Ltd in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Benitec Biopharma's stock prices. When investing in Benitec Biopharma, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Benitec Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Benitec Biopharma carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
How important is Benitec Biopharma's Liquidity
Benitec Biopharma financial leverage refers to using borrowed capital as a funding source to finance Benitec Biopharma Ltd ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Benitec Biopharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Benitec Biopharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Benitec Biopharma's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Benitec Biopharma's total debt and its cash.
Benitec Biopharma Gross Profit
Benitec Biopharma Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Benitec Biopharma previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Benitec Biopharma Gross Profit growth over the last 10 years. Please check Benitec Biopharma's gross profit and other fundamental indicators for more details.
Detailed Perspective On Benitec Biopharma
The market capitalization of Benitec Biopharma is $2.41 Billion. Almost 89.0 percent of Benitec Biopharma outstanding shares are held by regular investors with 0.48 (percent) owned by insiders and only 10.1 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Benitec Biopharma Ltd. Please refer to our Terms of Use for any information regarding our disclosure principles.